International Myeloma Foundation Celebrates ODAC Meeting Outcome on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval of Myeloma Drugs in Clinical Trials: A Huge Win for the Global Myeloma Community
April 12, 2024 16:08 ET
|
International Myeloma Foundation
International Myeloma Foundation Celebrates ODAC Meeting on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval.
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
March 28, 2024 17:16 ET
|
Burning Rock Biotech Limited
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
March 21, 2024 21:40 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and...
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
February 27, 2024 09:15 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National...
Burning Rock Announces Receipt of Notification from NASDAQ
January 04, 2024 01:03 ET
|
Burning Rock Biotech Limited
Burning Rock Announces Receipt of Notification from NASDAQ
Burning Rock Announces Results of 2023 Annual General Meeting
December 19, 2023 21:35 ET
|
Burning Rock Biotech Limited
Burning Rock Announces Results of 2023 Annual General Meeting
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
December 09, 2023 08:30 ET
|
Adaptive Biotechnologies
Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD assessed from blood in multiple myeloma may be an indicator...
Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023
November 20, 2023 20:55 ET
|
Burning Rock Biotech Limited
Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
September 18, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan...
Adaptive Announces Launch of Epic Integration for clonoSEQ®
September 13, 2023 07:30 ET
|
Adaptive Biotechnologies
SEATTLE, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...